Susan Knox

Radiation oncologist

Associate Professor of Radiation Oncology

Radiation Oncology

  • 875 Blake Wilbur Drive
  • Palo Alto, CA 94304
  • Phone: 650-498-6000
Learn More About the Clinic Getting Here Make An Appointment

Breast Cancer Program

  • 900 Blake Wilbur Drive
  • Palo Alto, CA 94304
  • Phone: 650-498-6004
Learn More About the Clinic Getting Here Make An Appointment

Hematology Program

  • 875 Blake Wilbur Drive
  • Palo Alto, CA 94304
  • Phone: 650-498-6000
Learn More About the Clinic Getting Here Make An Appointment

Lymphoma Program

  • 875 Blake Wilbur Drive
  • Palo Alto, CA 94304
  • Phone: 650-498-6000
Learn More About the Clinic Getting Here Make An Appointment

Skin Cancer Program

  • 900 Blake Wilbur Drive
  • Palo Alto, CA 94304
  • Phone: 650-498-6000
Learn More About the Clinic Getting Here Make An Appointment

Professional Education

Residency: Stanford University School of Medicine (1990) CA

Fellowship: Stanford University School of Medicine (1989) CA

Internship: UC Davis Medical Center (1986) CA

Medical Education: Stanford University School of Medicine (1985) CA

Post Doc Fellow, Stanford Univ. Hospital, Medical Oncology (1989)

Medical Intern, UC Davis, California (1986)

Post-Doc Fellow/Res. Assist., Stanford Univ. Hospital, Medical Oncology (1989)

MD, Stanford University (1985)

Post-Doc Res. Immunologist, UC Davis, California, Energy-Related Health Research

PhD, UC Davis, California (1980)

AB, UC Berkeley, California, (1974)

Honors & Awards

Leadership in Education, Stanford University School of Medicine (2008)

Clinical Oncology Career Development Award, American Cancer Society (1991-94)

Lazard Faculty Scholar, Lazard Faculty (1992-93)

Board of Governors, Stanford Medical Alumni Association (2000-2008)

Charles F. Kettering Selection Committee, General Motors Cancer Research Foundation (2000-2002)

Elected Councilor Medicine, Radiation Research Society (2003)

President, Alumni Association, Stanford University School of Medicine (2005-2007)

Administrative Appointments

Associate Professor (University Tenure Line), Stanford Univ. Sch. of Medicine (1997 - 2010)

Assistant Professor (University Tenure Line), Stanford Univ. Sch. of Medicine (1990 - 1997)

Assistant Dean for Medical Student Advising, Stanford Univ. Sch. of Medicine (2002 - 2010)

Member, Oncological Sciences Study Section Boundaries Team (2001 - 2001)

Member, Clinical Oncology Study Section (2001 - 2004)

Reviewer, External Advisory Committee for NIH grant U54 CA 90788 (2001 - 2006)

Reviewer, Cancer Research UK (2002 - 2008)

Reviewer, Advisory Board NIH T32 CA09695 (2005 - 2008)

Editorial Board Member, Antibody, Immunoconjugates and Radiopharmaceuticals (1992 - 1995)

Editorial Board Member, Cancer Biotherapy and Radiopharmaceuticals (1996 - 2008)

Associate Editor, Radiation Research (2000 - 2003)

Associate Editor, Journal of Clinical Oncology (2003 - 2006)

Executive Committee, Clinical Cancer Center (2003 - 2008)

Chair, Data and Safety Monitoring Committee, Stanford Clinical Trials Office, Cancer Center (2003 - 2003)

Director, Core: Protocol Review and Monitoring System, Stanford Cancer Center (2004 - 2008)

Medical Education Leadership Group, Stanford Cancer Center (2004 - 2008)

RIT Advisory Board, Society Nuclear Medicine (2006 - 2008)

Committee on the State of Science in Nuclear Medicine, Subcommittee on Targeted Radiotherapy, The National Academies (2006 - 2008)

Item Writer of the written examination in the category of Radiobiology, American Board of Radiology (2007 - 2007)

The Molecular Therapeutics Program, Cancer Center (2008 - 2008)

Clinical Trials

Clinical trials are research studies that evaluate a new medical approach, device, drug, or other treatment. As a Stanford Health Care patient, you have access to the latest, advanced clinical trials.

Open trials refer to studies currently accepting participants. Closed trials are not currently enrolling, but may open in the future.

The implications of hyponitroxia in cancer
Oronsky, B., Fanger, G., Oronsky, N., Knox, S. J., & Scicinski, J. (2014). The implications of hyponitroxia in cancer. Translational Oncology, 7(2).

Novel nitric oxide generating compound glycidyl nitrate enhances the therapeutic efficacy of chemotherapy and radiotherapy
Ning, S., Bednarski, M., Oronsky, B., Scicinski, J., & Knox, S. J. (2014). Novel nitric oxide generating compound glycidyl nitrate enhances the therapeutic efficacy of chemotherapy and radiotherapy. Biochemical and Biophysical Research Communications, 447(3).

Two Case Reports of Resensitization to Previous Chemotherapy with the Novel Hypoxia-Activated Hypomethylating Anticancer Agent RRx-001 in Metastatic Colorectal Cancer Patients
Reid, T., Dad, S., Korn, R., Oronsky, G., Knox, S. J., & Scicinski, J. (2014). Two Case Reports of Resensitization to Previous Chemotherapy with the Novel Hypoxia-Activated Hypomethylating Anticancer Agent RRx-001 in Metastatic Colorectal Cancer Patients. Case Reports in Oncology, 7(1).

Real Time Dynamic Imaging and Current Targeted Therapies in the War on Cancer: A New Paradigm
Paulmurugan, R., Oronsky, B., Brouse, C. F., Reid, T., Knox, S., & Scicinski, J. (2013). Real Time Dynamic Imaging and Current Targeted Therapies in the War on Cancer: A New Paradigm. THERANOSTICS, 3(6), 437-447.

Characterization of direct radiation-induced immune function and molecular signaling changes in an antigen presenting cell line.
Parker, J. J., Jones, J. C., Strober, S., & Knox, S. J. (2013). Characterization of direct radiation-induced immune function and molecular signaling changes in an antigen presenting cell line. Clinical immunology (Orlando, Fla.), 148(1), 44-55.

Topical hypochlorite ameliorates NF-kB-mediated skin diseases in mice
Leung, T. H., Zhang, L. F., Wang, J., Ning, S., Knox, S. K., & Kim, S. K. (2013). Topical hypochlorite ameliorates NF-kB-mediated skin diseases in mice. The Journal of Clinical Investigation, 123(12).

A Systemic Complete Response of Metastatic Melanoma to Local Radiation and Immunotherapy
Hiniker, S. M., Chen, D. S., Reddy, S., Chang, D. T., Jones, J. C., & Knox, S. J. (2012). A Systemic Complete Response of Metastatic Melanoma to Local Radiation and Immunotherapy. TRANSLATIONAL ONCOLOGY, 5(6), 404-407.

The Scarlet Letter of Alkylation: A Mini Review of Selective Alkylating Agents
Oronsky, B. T., Reid, T., Knox, S. J., & Scicinski, J. J. (2012). The Scarlet Letter of Alkylation: A Mini Review of Selective Alkylating Agents. TRANSLATIONAL ONCOLOGY, 5(4), 226-229.

Mitigation of Radiation-Induced Dermatitis by Activation of Aldehyde Dehydrogenase 2 Using Topical Alda-1 in Mice
Ning, S., Budas, G. R., Churchill, E. N., Chen, C.-H., Knox, S. J., & Mochly-Rosen, D. (2012). Mitigation of Radiation-Induced Dermatitis by Activation of Aldehyde Dehydrogenase 2 Using Topical Alda-1 in Mice. RADIATION RESEARCH, 178(1), 69-74.

Darinaparsin: Solid Tumor Hypoxic Cytotoxin and Radiosensitizer
Tian, J., Zhao, H., Nolley, R., Reese, S. W., Young, S. R., & Knox, S. J. (2012). Darinaparsin: Solid Tumor Hypoxic Cytotoxin and Radiosensitizer. CLINICAL CANCER RESEARCH, 18(12), 3366-3376.

Beyond Antiangiogenesis: Vascular Modulation as an Anticancer Therapy-A Review
Oronsky, B. T., Scicinski, J. J., Reid, T., & Knox, S. (2012). Beyond Antiangiogenesis: Vascular Modulation as an Anticancer Therapy-A Review. TRANSLATIONAL ONCOLOGY, 5(3), 133-140.

Abscopal Effect in a Patient with Melanoma
Hiniker, S. M., Chen, D. S., & Knox, S. J. (2012). Abscopal Effect in a Patient with Melanoma. NEW ENGLAND JOURNAL OF MEDICINE, 366(21), 2035-2035.

Dinitroazetidines Are a Novel Class of Anticancer Agents and Hypoxia-Activated Radiation Sensitizers Developed from Highly Energetic Materials
Ning, S., Bednarski, M., Oronsky, B., Scicinski, J., Saul, G., & Knox, S. J. (2012). Dinitroazetidines Are a Novel Class of Anticancer Agents and Hypoxia-Activated Radiation Sensitizers Developed from Highly Energetic Materials. CANCER RESEARCH, 72(10), 2600-2608.

Is Nitric Oxide (NO) the Last Word in Radiosensitization? A Review
Oronsky, B. T., Knox, S. J., & Scicinski, J. J. (2012). Is Nitric Oxide (NO) the Last Word in Radiosensitization? A Review. TRANSLATIONAL ONCOLOGY, 5(2), 66-71.

Six degrees of separation: the oxygen effect in the development of radiosensitizers.
Oronsky, B. T., Knox, S. J., & Scicinski, J. (2011). Six degrees of separation: the oxygen effect in the development of radiosensitizers. Translational oncology, 4(4), 189-198.

Anti-tumor and radiosensitization activities of the iron chelator HDp44mT are mediated by effects on intracellular redox status
Tian, J., Peehl, D. M., Zheng, W., & Knox, S. J. (2010). Anti-tumor and radiosensitization activities of the iron chelator HDp44mT are mediated by effects on intracellular redox status. CANCER LETTERS, 298(2), 231-237.

In Situ Vaccination With a TLR9 Agonist Induces Systemic Lymphoma Regression: A Phase I/II Study
Brody, J. D., Ai, W. Z., Czerwinski, D. K., Torchia, J. A., Levy, M., & Levy, R. (2010). In Situ Vaccination With a TLR9 Agonist Induces Systemic Lymphoma Regression: A Phase I/II Study. JOURNAL OF CLINICAL ONCOLOGY, 28(28), 4324-4332.

Anti-alpha v Integrin Monoclonal Antibody Intetumumab Enhances the Efficacy of Radiation Therapy and Reduces Metastasis of Human Cancer Xenografts in Nude Rats
Ning, S., Tian, J., Marshall, D. J., & Knox, S. J. (2010). Anti-alpha v Integrin Monoclonal Antibody Intetumumab Enhances the Efficacy of Radiation Therapy and Reduces Metastasis of Human Cancer Xenografts in Nude Rats. CANCER RESEARCH, 70(19), 7591-7599.

SODIUM SELENITE RADIOSENSITIZES HORMONE-REFRACTORY PROSTATE CANCER XENOGRAFT TUMORS BUT NOT INTESTINAL CRYPT CELLS IN VIVO
Tian, J., Ning, S., & Knox, S. J. (2010). SODIUM SELENITE RADIOSENSITIZES HORMONE-REFRACTORY PROSTATE CANCER XENOGRAFT TUMORS BUT NOT INTESTINAL CRYPT CELLS IN VIVO. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 78(1), 230-236.

Metalloporphyrin Synergizes with Ascorbic Acid to Inhibit Cancer Cell Growth Through Fenton Chemistry
Tian, J., Peehl, D. M., & Knox, S. J. (2010). Metalloporphyrin Synergizes with Ascorbic Acid to Inhibit Cancer Cell Growth Through Fenton Chemistry. CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 25(4), 439-448.

I-131-Tositumomab (BexxarA (R)) vs. Y-90-Ibritumomab (ZevalinA (R)) Therapy of Low-Grade Refractory/Relapsed Non-Hodgkin Lymphoma
Iagaru, A., Mittra, E. S., Ganjoo, K., Knox, S. J., & Goris, M. L. (2010). I-131-Tositumomab (BexxarA (R)) vs. Y-90-Ibritumomab (ZevalinA (R)) Therapy of Low-Grade Refractory/Relapsed Non-Hodgkin Lymphoma. MOLECULAR IMAGING AND BIOLOGY, 12(2), 198-203.

Impact of Rituximab Treatment on Y-90-Ibritumomab Dosimetry for Patients with Non-Hodgkin Lymphoma
Shen, S., Forero, A., Meredith, R. F., Shah, J. J., Knox, S. J., & LoBuglio, A. F. (2010). Impact of Rituximab Treatment on Y-90-Ibritumomab Dosimetry for Patients with Non-Hodgkin Lymphoma. JOURNAL OF NUCLEAR MEDICINE, 51(1), 150-157.

Lanreotide promotes apoptosis and is not radioprotective in GH3 cells
Ning, S., Knox, S. J., Harsh, G. R., Culler, M. D., & Katznelson, L. (2009). Lanreotide promotes apoptosis and is not radioprotective in GH3 cells. ENDOCRINE-RELATED CANCER, 16(3), 1045-1055.

Selenite treatment inhibits LAPC-4 tumor growth and prostate-specific antigen secretion in a xenograft model of human prostate cancer
Bhattacharyya, R. S., Husbeck, B., Feldman, D., & Knox, S. J. (2008). Selenite treatment inhibits LAPC-4 tumor growth and prostate-specific antigen secretion in a xenograft model of human prostate cancer. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 72(3), 935-940.

Risks to normal tissues from radionuclide therapy
Meredith, R., Wessels, B., & Knox, S. (2008). Risks to normal tissues from radionuclide therapy. SEMINARS IN NUCLEAR MEDICINE, 38(5), 347-357.

Anti-integrin monoclonal antibody CNTO 95 enhances the therapeutic efficacy of fractionated radiation therapy in vivo
Ning, S., Nemeth, J. A., Hanson, R. L., Forsythe, K., & Knox, S. J. (2008). Anti-integrin monoclonal antibody CNTO 95 enhances the therapeutic efficacy of fractionated radiation therapy in vivo. MOLECULAR CANCER THERAPEUTICS, 7(6), 1569-1578.

MIRD continuing education: Bystander and low-dose-rate effects: Are these relevant to Radionuclide therapy?
Sgouros, G., Knox, S. J., Joiner, M. C., Morgan, W. F., & Kassis, A. I. (2007). MIRD continuing education: Bystander and low-dose-rate effects: Are these relevant to Radionuclide therapy?. JOURNAL OF NUCLEAR MEDICINE, 48(10), 1683-1691.

Expression and function of erythropoietin receptors in tumors - Implications for the use of erythropoiesis-stimulating agents in cancer patients
Sinclair, A. M., Todd, M. D., Forsythe, K., Knox, S. J., Elliott, S., & Begley, C. G. (2007). Expression and function of erythropoietin receptors in tumors - Implications for the use of erythropoiesis-stimulating agents in cancer patients. CANCER, 110(3), 477-488.

Targeting integrins and PI3K/Akt-mediated signal transduction pathways enhances radiation-induced anti-angiogenesis
Ning, S., Chen, Z., Dirks, A., Husbeck, B., Hsu, M., & Knox, S. J. (2007). Targeting integrins and PI3K/Akt-mediated signal transduction pathways enhances radiation-induced anti-angiogenesis. RADIATION RESEARCH, 168(1), 125-133.

Clinical efficacy of zanolimumab (HuMax-CD4): two phase 2 studies in refractory cutaneous T-cell lymphoma
Kim, Y. H., Duvic, M., Obitz, E., Gniadecki, R., Iversen, L., & Knox, S. J. (2007). Clinical efficacy of zanolimumab (HuMax-CD4): two phase 2 studies in refractory cutaneous T-cell lymphoma. BLOOD, 109(11), 4655-4662.

Inhibition of androgen receptor signaling by selenite and methylseleninic acid in prostate cancer cells: two distinct mechanisms of action
Husbeck, B., Bhattacharyya, R. S., Feldman, D., & Knox, S. J. (2006). Inhibition of androgen receptor signaling by selenite and methylseleninic acid in prostate cancer cells: two distinct mechanisms of action. MOLECULAR CANCER THERAPEUTICS, 5(8), 2078-2085.

Optimization of combination therapy of arsenic trioxide and fractionated radiotherapy for malignant glioma
Ning, S., & Knox, S. J. (2006). Optimization of combination therapy of arsenic trioxide and fractionated radiotherapy for malignant glioma. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 65(2), 493-498.

Phase I study of I-131-chimeric(ch) TNT-1/B monoclonal antibody for the treatment of advanced colon cancer
Street, H. H., Goris, M. L., Fisher, G. A., Wessels, B. W., Cho, C., & Knox, S. J. (2006). Phase I study of I-131-chimeric(ch) TNT-1/B monoclonal antibody for the treatment of advanced colon cancer. CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 21(3), 243-256.

Radiation sensitization with redox modulators: A promising approach
Rosenberg, A., & Knox, S. (2006). Radiation sensitization with redox modulators: A promising approach. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 64(2), 343-354.

Tumor-selective killing by selenite in patient-matched pairs of normal and malignant prostate cells
Husbeck, B., Nonn, L., Peehl, D. M., & Knox, S. J. (2006). Tumor-selective killing by selenite in patient-matched pairs of normal and malignant prostate cells. PROSTATE, 66(2), 218-225.

Clinical manifestations of noncoronary atherosclerotic vascular disease after moderate dose irradiation
Patel, D. A., Kochanski, J., Suen, A. W., Fajardo, L. F., Hancock, S. L., & Knox, S. J. (2006). Clinical manifestations of noncoronary atherosclerotic vascular disease after moderate dose irradiation. CANCER, 106(3), 718-725.

Clinical development of radioimmunotherapy for B-cell non-Hodgkin's lymphoma
Meredith, R. F., & Knox, S. J. (2006). Clinical development of radioimmunotherapy for B-cell non-Hodgkin's lymphoma. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 66(2), S15-S22.

Re-treatment with I-131 tositumomab in patients with non-Hodgkin's lymphoma who had previously responded to I-131 tositumomab
Kaminski, M. S., Radford, J. A., Gregory, S. A., Leonard, J. P., Knox, S. J., & Wahl, R. L. (2005). Re-treatment with I-131 tositumomab in patients with non-Hodgkin's lymphoma who had previously responded to I-131 tositumomab. JOURNAL OF CLINICAL ONCOLOGY, 23(31), 7985-7993.

Tositumomab and iodine-131 tositumomab produces durable complete remissions in a subset of heavily pretreated patients with low-grade and transformed non-Hodgkin's lymphomas
Fisher, R. I., Kaminski, M. S., Wahl, R. L., Knox, S. J., Zelenetz, A. D., & Coleman, M. (2005). Tositumomab and iodine-131 tositumomab produces durable complete remissions in a subset of heavily pretreated patients with low-grade and transformed non-Hodgkin's lymphomas. JOURNAL OF CLINICAL ONCOLOGY, 23(30), 7565-7573.

Assessment of treatment-related myelodysplastic syndromes and acute myeloid leukemia in patients with non-Hodgkin lymphoma treated with tositumomab and iodine I-131 tositumomab
Bennett, J. M., Kaminski, M. S., Leonard, J. P., Vose, J. M., Zelenetz, A. D., & Capizzi, R. L. (2005). Assessment of treatment-related myelodysplastic syndromes and acute myeloid leukemia in patients with non-Hodgkin lymphoma treated with tositumomab and iodine I-131 tositumomab. BLOOD, 105(12), 4576-4582.

Redox modulation of human prostate carcinoma cells by selenite increases radiation-induced cell killing
Husbeck, B., Peehl, D. M., & Knox, S. J. (2005). Redox modulation of human prostate carcinoma cells by selenite increases radiation-induced cell killing. FREE RADICAL BIOLOGY AND MEDICINE, 38(1), 50-57.

Darbepoietin alfa potentiates the efficacy of radiation therapy in mice with corrected or uncorrected anemia
Ning, S. C., Hartley, C., Molineux, G., & Knox, S. J. (2005). Darbepoietin alfa potentiates the efficacy of radiation therapy in mice with corrected or uncorrected anemia. CANCER RESEARCH, 65(1), 284-290.

The radioisotope contributes significantly to the activity of radioimmunotherapy
Davis, T. A., Kaminski, M. S., Leonard, J. P., Hsu, F. J., Wilkinson, M., & Knox, S. J. (2004). The radioisotope contributes significantly to the activity of radioimmunotherapy. CLINICAL CANCER RESEARCH, 10(23), 7792-7798.

Enhancement of the efficacy of an antagonist of an extracellular receptor by attachment to the surface of a biocompatible carrier
Wartchow, C. A., Alters, S. E., Garzone, P. D., Li, L. Y., Choi, S., & Cleland, J. L. (2004). Enhancement of the efficacy of an antagonist of an extracellular receptor by attachment to the surface of a biocompatible carrier. PHARMACEUTICAL RESEARCH, 21(10), 1880-1885.

Increased cure rate of glioblastoma using concurrent therapy with radiotherapy and arsenic trioxide
Ning, S. C., & Knox, S. J. (2004). Increased cure rate of glioblastoma using concurrent therapy with radiotherapy and arsenic trioxide. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 60(1), 197-203.

Enhanced effectiveness of radiochemotherapy with tirapazamine by local application of electric pulses to tumors
Maxim, P. G., Carson, J. Jl., Ning, S. C., Knox, S. J., Boyer, A. L., & Walleczek, J. (2004). Enhanced effectiveness of radiochemotherapy with tirapazamine by local application of electric pulses to tumors. RADIATION RESEARCH, 162(2), 185-193.

Radiobiology of radioimmunotherapy: Targeting CD20 B-cell antigen in non-Hodgkin's lymphoma
Hernandez, M. C., & Knox, S. J. (2004). Radiobiology of radioimmunotherapy: Targeting CD20 B-cell antigen in non-Hodgkin's lymphoma. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 59(5), 1274-1287.

Phase 1 trial of a novel anti-CD20 fusion protein in pretargeted radioimmunotherapy for B-cell non-Hodgkin lymphoma
Forero, A., Weiden, P. L., Vose, J. M., Knox, S. J., LoBuglio, A. F., & Meredith, R. F. (2004). Phase 1 trial of a novel anti-CD20 fusion protein in pretargeted radioimmunotherapy for B-cell non-Hodgkin lymphoma. BLOOD, 104(1), 227-236.

Dosimetry model for radioactivity localized to intestinal mucosa
Fisher, D., Rajon, D., Breitz, H., Goris, M., Bolch, W., & Knox, S. (2004). Dosimetry model for radioactivity localized to intestinal mucosa. CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 19(3), 293-307.

A novel antiangiogenesis therapy using an integrin antagonist or anti-FLK-1 antibody coated Y-90-labeled nanoparticles
Li, L. Y., Wartchow, C. A., Danthi, S. N., Shen, Z. M., DeChene, N., & Knox, S. J. (2004). A novel antiangiogenesis therapy using an integrin antagonist or anti-FLK-1 antibody coated Y-90-labeled nanoparticles. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 58(4), 1215-1227.

Radiation-induced cyclooxygenase 2 up-regulation is dependent on redox status in prostate cancer cells
Li, L. Y., Steinauer, K. K., Dirks, A. J., Husbeck, B., Gibbs, I., & Knox, S. J. (2003). Radiation-induced cyclooxygenase 2 up-regulation is dependent on redox status in prostate cancer cells. RADIATION RESEARCH, 160(6), 617-621.

Radiobiology of radioimmunotherapy with Y-90 ibritumomab tiuxetan (Zevalin)
Hernandez, M. C., & Knox, S. J. (2003). Radiobiology of radioimmunotherapy with Y-90 ibritumomab tiuxetan (Zevalin). SEMINARS IN ONCOLOGY, 30(6), 6-10.

Distribution of monoclonal antiferritin antibody in Kaposi's sarcoma, Hodgkin's disease, and hepatocellular carcinoma
Yuen, A. R., Higgins, J. P., Baker, R., Kamel, O. W., Warnke, R. A., & Knox, S. J. (2003). Distribution of monoclonal antiferritin antibody in Kaposi's sarcoma, Hodgkin's disease, and hepatocellular carcinoma. HUMAN PATHOLOGY, 34(4), 381-384.

Role of glutathione depletion and reactive oxygen species generation in apoptotic signaling in a human B lymphoma cell line
Armstrong, J. S., Steinauer, K. K., Hornung, B., Irish, J. M., Lecane, P., & Knox, S. J. (2002). Role of glutathione depletion and reactive oxygen species generation in apoptotic signaling in a human B lymphoma cell line. CELL DEATH AND DIFFERENTIATION, 9(3), 252-263.

The antiangiogenic agents SU5416 and SU6668 increase the antitumor effects of fractionated irradiation
Ning, S. C., Laird, D., Cherrington, J. M., & Knox, S. J. (2002). The antiangiogenic agents SU5416 and SU6668 increase the antitumor effects of fractionated irradiation. RADIATION RESEARCH, 157(1), 45-51.

Rotenone-induced G2/M cell cycle arrest and apoptosis in a human B lymphoma cell line PW
Armstrong, J. S., Hornung, B., Lecane, P., Jones, D. P., & Knox, S. J. (2001). Rotenone-induced G2/M cell cycle arrest and apoptosis in a human B lymphoma cell line PW. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 289(5), 973-978.

Radioimmunotherapy of B-cell NHL.
Meredith, R. F., & Knox, S. J. (2001). Radioimmunotherapy of B-cell NHL. Current pharmaceutical biotechnology, 2(4), 327-339.

Pivotal study of iodine I 131 Tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas
Kaminski, M. S., Zelenetz, A. D., Press, O. W., Saleh, M., Leonard, J., & Vose, J. M. (2001). Pivotal study of iodine I 131 Tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas. JOURNAL OF CLINICAL ONCOLOGY, 19(19), 3918-3928.

Bcl-2 inhibits apoptosis induced by mitochondrial uncoupling but does not prevent mitochondrial transmembrane depolarization
Armstrong, J. S., Steinauer, K. K., French, J., Killoran, P. L., Walleczek, J., & Knox, S. J. (2001). Bcl-2 inhibits apoptosis induced by mitochondrial uncoupling but does not prevent mitochondrial transmembrane depolarization. EXPERIMENTAL CELL RESEARCH, 262(2), 170-179.

Long-term follow-up of patients with Stage III follicular lymphoma treated with primary radiotherapy at Stanford University
Murtha, A. D., Knox, S. J., Hoppe, R. T., Rupnow, B. A., & Hanson, J. (2001). Long-term follow-up of patients with Stage III follicular lymphoma treated with primary radiotherapy at Stanford University. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 49(1), 3-15.

Radiation induces upregulation of cyclooxygenase-2 (COX-2) protein in PC-3 cells
Steinauer, K. K., Gibbs, I., Ning, S. C., French, J. N., Armstrong, J., & Knox, S. J. (2000). Radiation induces upregulation of cyclooxygenase-2 (COX-2) protein in PC-3 cells. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 48(2), 325-328.

Bcl-2 overexpression results in enhanced capacitative calcium entry and resistance to SKF-96395-induced apoptosis
Williams, S. S., French, J. N., Gilbert, M., Rangaswami, A. A., Walleczek, J., & Knox, S. J. (2000). Bcl-2 overexpression results in enhanced capacitative calcium entry and resistance to SKF-96395-induced apoptosis. CANCER RESEARCH, 60(16), 4358-4361.

Clinical radioimmunotherapy
Knox, S. J., & Meredith, R. F. (2000). Clinical radioimmunotherapy. SEMINARS IN RADIATION ONCOLOGY, 10(2), 73-93.

Multicenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin's lymphomas
Vose, J. M., Wahl, R. L., Saleh, M., Rohatiner, A. Z., Knox, S. J., & Kaminski, M. S. (2000). Multicenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin's lymphomas. JOURNAL OF CLINICAL ONCOLOGY, 18(6), 1316-1323.

Phase II trial of yttrium-90-DOTA-biotin pretargeted by NR-LU-10 antibody/streptavidin in patients with metastatic colon cancer
Knox, S. J., Goris, M. L., Tempero, M., Weiden, P. L., Gentner, L., & Weiner, L. M. (2000). Phase II trial of yttrium-90-DOTA-biotin pretargeted by NR-LU-10 antibody/streptavidin in patients with metastatic colon cancer. CLINICAL CANCER RESEARCH, 6(2), 406-414.

Introduction
Knox, S. J. (2000). Introduction. Seminars in radiation oncology, 10(2), 71-2.

Radiation absorbed dose estimation for Y-90-DOTA-biotin with pretargeted NR-LU-10/streptavidin
Breitz, H. B., Fisher, D. R., Goris, M. L., Knox, S., Ratliff, B., & Weiden, P. L. (1999). Radiation absorbed dose estimation for Y-90-DOTA-biotin with pretargeted NR-LU-10/streptavidin. CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 14(5), 381-395.

G(2)/M-phase arrest and death by apoptosis of HL60 cells irradiated with exponentially decreasing low-dose-rate gamma radiation
Ning, S. C., & Knox, S. J. (1999). G(2)/M-phase arrest and death by apoptosis of HL60 cells irradiated with exponentially decreasing low-dose-rate gamma radiation. RADIATION RESEARCH, 151(6), 659-669.

The role of radiation-induced apoptosis as a determinant of tumor responses to radiation therapy
Rupnow, B. A., & Knox, S. J. (1999). The role of radiation-induced apoptosis as a determinant of tumor responses to radiation therapy. APOPTOSIS, 4(2), 115-143.

Radiosensitization by intratumoral administration of cisplatin in a sustained-release drug delivery system
Ning, S. C., Yu, N., Brown, D. M., Kanekal, S., & Knox, S. J. (1999). Radiosensitization by intratumoral administration of cisplatin in a sustained-release drug delivery system. RADIOTHERAPY AND ONCOLOGY, 50(2), 215-223.

Myc activation reduces fibroblast clonogenicity via an apoptotic mechanism that can be suppressed by a soluble paracrine factor
Rupnow, B. A., Murtha, A. D., Chen, E., & Knox, S. J. (1998). Myc activation reduces fibroblast clonogenicity via an apoptotic mechanism that can be suppressed by a soluble paracrine factor. CANCER LETTERS, 127(1-2), 211-219.

Direct evidence that apoptosis enhances tumor responses to fractionated radiotherapy
Rupnow, B. A., Murtha, A. D., Alarcon, R. M., Giaccia, A. J., & Knox, S. J. (1998). Direct evidence that apoptosis enhances tumor responses to fractionated radiotherapy. CANCER RESEARCH, 58(9), 1779-1784.

p53 mediates apoptosis induced by c-Myc activation in hypoxic or gamma irradiated fibroblasts
Rupnow, B. A., Alarcon, R. M., Giaccia, A. J., & Knox, S. J. (1998). p53 mediates apoptosis induced by c-Myc activation in hypoxic or gamma irradiated fibroblasts. CELL DEATH AND DIFFERENTIATION, 5(2), 141-147.

Effects of keratinocyte growth factor on the proliferation and radiation survival of human squamous cell carcinoma cell lines in vitro and in vivo
Ning, S. C., Shui, C. X., Khan, W. B., Benson, W., Lacey, D. L., & Knox, S. J. (1998). Effects of keratinocyte growth factor on the proliferation and radiation survival of human squamous cell carcinoma cell lines in vitro and in vivo. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 40(1), 177-187.

Radiobiologic studies of radioimmunotherapy and external beam radiotherapy in vitro and in vivo in human renal cell carcinoma xenografts
Ning, S. C., Trisler, K., Wessels, B. W., & Knox, S. J. (1997). Radiobiologic studies of radioimmunotherapy and external beam radiotherapy in vitro and in vivo in human renal cell carcinoma xenografts. CANCER, 80(12), 2519-2528.

A prospective study of radiation therapy-associated thrombocytopenia
Knox, S. J., Varghese, A., Khan, W., Chen, E., MacManus, M., & Lamborn, K. R. (1997). A prospective study of radiation therapy-associated thrombocytopenia. BLOOD, 90(10), 4237-4238.

Enhancement of murine intestinal stem cell survival after irradiation by keratinocyte growth factor
Khan, W. B., Shui, C. X., Ning, S. C., & Knox, S. J. (1997). Enhancement of murine intestinal stem cell survival after irradiation by keratinocyte growth factor. RADIATION RESEARCH, 148(3), 248-253.

Influence of Bcl-2 overexpression on Na+/K+-ATPase pump activity: Correlation with radiation-induced programmed cell death
Gilbert, M., & Knox, S. (1997). Influence of Bcl-2 overexpression on Na+/K+-ATPase pump activity: Correlation with radiation-induced programmed cell death. JOURNAL OF CELLULAR PHYSIOLOGY, 171(3), 299-304.

Radiotherapy-associated neutropenia and thrombocytopenia: Analysis of risk factors and development of a predictive model
MacManus, M., Lamborn, K., Khan, W., Varghese, A., Graef, L., & Knox, S. (1997). Radiotherapy-associated neutropenia and thrombocytopenia: Analysis of risk factors and development of a predictive model. BLOOD, 89(7), 2303-2310.

Modulation of c-myc activity and apoptosis in vivo
Alarcon, R. M., Rupnow, B. A., Graeber, T. G., Knox, S. J., & Giaccia, A. J. (1996). Modulation of c-myc activity and apoptosis in vivo. CANCER RESEARCH, 56(19), 4315-4319.

Treatment of hormone-refractory prostate cancer with Y-90-CYT-356 monoclonal antibody
Deb, N., Goris, M., Trisler, K., Fowler, S., Saal, J., & Knox, S. (1996). Treatment of hormone-refractory prostate cancer with Y-90-CYT-356 monoclonal antibody. CLINICAL CANCER RESEARCH, 2(8), 1289-1297.

Association of BCL-2 with membrane hyperpolarization and radioresistance
Gilbert, M. S., Saad, A. H., Rupnow, B. A., & Knox, S. J. (1996). Association of BCL-2 with membrane hyperpolarization and radioresistance. JOURNAL OF CELLULAR PHYSIOLOGY, 168(1), 114-122.

Intratumoral radioimmunotherapy of a human colon cancer xenograft using a sustained-release gel
Ning, S., Trisler, K., Brown, D. M., Yu, N. Y., Kanekal, S., & Knox, S. J. (1996). Intratumoral radioimmunotherapy of a human colon cancer xenograft using a sustained-release gel. RADIOTHERAPY AND ONCOLOGY, 39(2), 179-189.

Over-expression of Bcl-2 protects against apoptosis induced by the bioreductive cytotoxic drug SR4233 (tirapazamine)
Gilbert, M. S., Rupnow, B. A., Ramirez, D. A., Trisler, K. D., & Knox, S. J. (1996). Over-expression of Bcl-2 protects against apoptosis induced by the bioreductive cytotoxic drug SR4233 (tirapazamine). CELL DEATH AND DIFFERENTIATION, 3(2), 215-222.

Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma
Knox, S. J., Goris, M. L., Trisler, K., Negrin, R., Davis, T., & Levy, R. (1996). Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma. CLINICAL CANCER RESEARCH, 2(3), 457-470.

Treatment of cutaneous T-Cell lymphoma with chimeric anti-CD4 monoclonal antibody
Knox, S., Hoppe, R. T., Maloney, D., Gibbs, I., Fowler, S., & Levy, R. (1996). Treatment of cutaneous T-Cell lymphoma with chimeric anti-CD4 monoclonal antibody. BLOOD, 87(3), 893-899.

Overview of studies on experimental radioimmunotherapy.
Knox, S. J. (1995). Overview of studies on experimental radioimmunotherapy. Cancer research, 55(23), 5832s-5836s.

EFFECTS OF STEM-CELL FACTOR ON THE GROWTH AND RADIATION SURVIVAL OF TUMOR-CELLS
Shui, C. X., Khan, W. B., Leigh, B. R., Turner, A. M., Wilder, R. B., & Knox, S. J. (1995). EFFECTS OF STEM-CELL FACTOR ON THE GROWTH AND RADIATION SURVIVAL OF TUMOR-CELLS. CANCER RESEARCH, 55(15), 3431-3437.

MULTIPLE COURSES OF HIGH-DOSE TOTAL SKIN ELECTRON-BEAM THERAPY IN THE MANAGEMENT OF MYCOSIS-FUNGOIDES
Becker, M., Hoppe, R. T., & Knox, S. J. (1995). MULTIPLE COURSES OF HIGH-DOSE TOTAL SKIN ELECTRON-BEAM THERAPY IN THE MANAGEMENT OF MYCOSIS-FUNGOIDES. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 32(5), 1445-1449.

STEM-CELL FACTOR ENHANCES THE SURVIVAL OF MURINE INTESTINAL STEM-CELLS AFTER PHOTON IRRADIATION
Leigh, B. R., Khan, W., Hancock, S. L., & Knox, S. J. (1995). STEM-CELL FACTOR ENHANCES THE SURVIVAL OF MURINE INTESTINAL STEM-CELLS AFTER PHOTON IRRADIATION. RADIATION RESEARCH, 142(1), 12-15.

Radioimmunotherapy of the Non-Hodgkin's Lymphomas.
Knox, S. J. (1995). Radioimmunotherapy of the Non-Hodgkin's Lymphomas. Seminars in radiation oncology, 5(4), 331-341.

STEM-CELL FACTOR ENHANCES THE SURVIVAL OF IRRADIATED HUMAN BONE-MARROW MAINTAINED IN SCID MICE
Leigh, B. R., Webb, S., Hancock, S. L., & Knox, S. J. (1994). STEM-CELL FACTOR ENHANCES THE SURVIVAL OF IRRADIATED HUMAN BONE-MARROW MAINTAINED IN SCID MICE. STEM CELLS, 12(4), 430-435.

ORGAN MODELING IN THE QUANTITATION OF PLANAR IMAGES FOR DISTRIBUTION STUDIES
Goris, M. L., Knox, S. A., Nielsen, K. R., & BOUILLANT, O. (1994). ORGAN MODELING IN THE QUANTITATION OF PLANAR IMAGES FOR DISTRIBUTION STUDIES. CANCER, 73(3), 919-922.

EFFECT OF FILGRASTIM (G-CSF) IN HODGKINS-DISEASE PATIENTS TREATED WITH RADIATION
Knox, S. J., Fowler, S., Marquez, C., & Hoppe, R. T. (1994). EFFECT OF FILGRASTIM (G-CSF) IN HODGKINS-DISEASE PATIENTS TREATED WITH RADIATION. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 28(2), 445-450.

THE HYPOXIC CYTOTOXIN SR-4233 INCREASES THE EFFECTIVENESS OF RADIOIMMUNOTHERAPY IN MICE WITH HUMAN NON-HODGKINS-LYMPHOMA XENOGRAFTS
Wilder, R. B., McGann, J. K., SUTHERLAND, W. R., Waller, E. K., Minchinton, A. I., & Knox, S. J. (1994). THE HYPOXIC CYTOTOXIN SR-4233 INCREASES THE EFFECTIVENESS OF RADIOIMMUNOTHERAPY IN MICE WITH HUMAN NON-HODGKINS-LYMPHOMA XENOGRAFTS. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 28(1), 119-126.

THE EFFECT OF STEM-CELL FACTOR ON IRRADIATED HUMAN BONE-MARROW
Leigh, B. R., Hancock, S. L., & Knox, S. J. (1993). THE EFFECT OF STEM-CELL FACTOR ON IRRADIATED HUMAN BONE-MARROW. CANCER RESEARCH, 53(17), 3857-3859.

CORRELATION OF TUMOR SENSITIVITY TO LOW-DOSE-RATE IRRADIATION WITH G2/M-PHASE BLOCK AND OTHER RADIOBIOLOGICAL PARAMETERS
Knox, S. J., Sutherland, W., & Goris, M. L. (1993). CORRELATION OF TUMOR SENSITIVITY TO LOW-DOSE-RATE IRRADIATION WITH G2/M-PHASE BLOCK AND OTHER RADIOBIOLOGICAL PARAMETERS. RADIATION RESEARCH, 135(1), 24-31.

LOCAL HYPERTHERMIA AND SR-4233 ENHANCE THE ANTITUMOR EFFECTS OF RADIOIMMUNOTHERAPY IN NUDE-MICE WITH HUMAN COLONIC ADENOCARCINOMA XENOGRAFTS
Wilder, R. B., Langmuir, V. K., Mendonca, H. L., Goris, M. L., & Knox, S. J. (1993). LOCAL HYPERTHERMIA AND SR-4233 ENHANCE THE ANTITUMOR EFFECTS OF RADIOIMMUNOTHERAPY IN NUDE-MICE WITH HUMAN COLONIC ADENOCARCINOMA XENOGRAFTS. CANCER RESEARCH, 53(13), 3022-3027.

RADIOBIOLOGY OF RADIOLABELED ANTIBODY THERAPY AS APPLIED TO TUMOR DOSIMETRY
Langmuir, V. K., Fowler, J. F., Knox, S. J., Wessels, B. W., SUTHERLAND, R. M., & Wong, J. Yc. (1993). RADIOBIOLOGY OF RADIOLABELED ANTIBODY THERAPY AS APPLIED TO TUMOR DOSIMETRY. MEDICAL PHYSICS, 20(2), 601-610.

Determinants of low dose rate effects associated with radioimmunotherapy.
Knox SJ, Sutherland W, & Goris ML. (1993). Determinants of low dose rate effects associated with radioimmunotherapy. Antibody Immunoconjugates and Radiopharmaceuticals, 6.

Response to letter by A. E. Amin regarding tumour size dependence of relative efficacy of radioimmunotherapy and external beam irradiation in tumour treatment.
Knox SJ, Goris ML, & Wessels BW. (1993). Response to letter by A. E. Amin regarding tumour size dependence of relative efficacy of radioimmunotherapy and external beam irradiation in tumour treatment. Radiotherapy Oncology, 25.

THE EFFECT OF UNLABELED MONOCLONAL-ANTIBODY (MAB) ON THE BIODISTRIBUTION OF I-131 ANTIIDIOTYPE MAB IN MURINE B-CELL LYMPHOMA
Schiele, J., Knox, S. J., RUEHL, W., & Goris, M. L. (1992). THE EFFECT OF UNLABELED MONOCLONAL-ANTIBODY (MAB) ON THE BIODISTRIBUTION OF I-131 ANTIIDIOTYPE MAB IN MURINE B-CELL LYMPHOMA. RADIOTHERAPY AND ONCOLOGY, 24(3), 169-176.

OVERVIEW OF ANIMAL STUDIES COMPARING RADIOIMMUNOTHERAPY WITH DOSE EQUIVALENT EXTERNAL BEAM IRRADIATION
Knox, S. J., Goris, M. L., & Wessels, B. W. (1992). OVERVIEW OF ANIMAL STUDIES COMPARING RADIOIMMUNOTHERAPY WITH DOSE EQUIVALENT EXTERNAL BEAM IRRADIATION. RADIOTHERAPY AND ONCOLOGY, 23(2), 111-117.

THE BIODISTRIBUTION OF IN-111 ANTI-BFGF IN A VARIETY OF TUMORS - CORRELATION WITH CELL-BINDING ASSAYS
Knox, S. J., Brown, J. M., McGann, J., Sutherland, W., Goris, M. L., & Gross, J. L. (1991). THE BIODISTRIBUTION OF IN-111 ANTI-BFGF IN A VARIETY OF TUMORS - CORRELATION WITH CELL-BINDING ASSAYS. ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, 638, 497-502.

RESULTS OF THE 1989 ASSOCIATION OF RESIDENTS IN RADIATION ONCOLOGY SURVEY
Corn, B. W., Taylor, B. W., Knox, S. J., Martz, K. L., & Flynn, D. F. (1991). RESULTS OF THE 1989 ASSOCIATION OF RESIDENTS IN RADIATION ONCOLOGY SURVEY. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 20(6), 1363-1367.

MYCOSIS-FUNGOIDES ARTHROPATHY
Berger, R. G., Knox, S. J., Levy, R., Sklar, J. L., Cohen, P., & Reichert, T. (1991). MYCOSIS-FUNGOIDES ARTHROPATHY. ANNALS OF INTERNAL MEDICINE, 114(7), 571-572.

OBSERVATIONS ON THE EFFECT OF CHIMERIC ANTI-CD4 MONOCLONAL-ANTIBODY IN PATIENTS WITH MYCOSIS-FUNGOIDES
Knox, S. J., Levy, R., Hodgkinson, S., Bell, R., Brown, S., & Reichert, T. (1991). OBSERVATIONS ON THE EFFECT OF CHIMERIC ANTI-CD4 MONOCLONAL-ANTIBODY IN PATIENTS WITH MYCOSIS-FUNGOIDES. BLOOD, 77(1), 20-30.

DETERMINANTS OF THE ANTITUMOR EFFECT OF RADIOLABELED MONOCLONAL-ANTIBODIES
Knox, S. J., Levy, R., MILLER, R. A., UHLAND, W., Schiele, J., & Goris, M. L. (1990). DETERMINANTS OF THE ANTITUMOR EFFECT OF RADIOLABELED MONOCLONAL-ANTIBODIES. CANCER RESEARCH, 50(16), 4935-4940.

THE CHANGING FACE OF RADIATION ONCOLOGY
Meredith, R. F., Halberg, F. E., & Knox, S. J. (1990). THE CHANGING FACE OF RADIATION ONCOLOGY. SOUTHERN MEDICAL JOURNAL, 83(4), 488-488.

HYPERTHERMIA AND RADIATION-THERAPY IN THE TREATMENT OF RECURRENT MERKEL CELL TUMORS
Knox, S. J., & Kapp, D. S. (1988). HYPERTHERMIA AND RADIATION-THERAPY IN THE TREATMENT OF RECURRENT MERKEL CELL TUMORS. CANCER, 62(8), 1479-1486.

2 INDEPENDENT PATHWAYS OF HELPER ACTIVITY PROVIDED BY A SINGLE T-CELL CLONE
Shigeta, M., Takahara, S., Knox, S. J., Ishihara, T., Vitetta, E. S., & Fathman, C. G. (1986). 2 INDEPENDENT PATHWAYS OF HELPER ACTIVITY PROVIDED BY A SINGLE T-CELL CLONE. JOURNAL OF IMMUNOLOGY, 136(1), 34-38.

EFFECT OF THYMOPOIETIN AND INTERLEUKIN-2 ON DEPRESSED MITOGENIC RESPONSIVENESS AND COLONY FORMATION OF LYMPHOCYTES FROM PATIENTS WITH PRELEUKEMIA
Knox, S. J., ROSENBLATT, L. S., Anderson, R. W., & Greenberg, B. R. (1986). EFFECT OF THYMOPOIETIN AND INTERLEUKIN-2 ON DEPRESSED MITOGENIC RESPONSIVENESS AND COLONY FORMATION OF LYMPHOCYTES FROM PATIENTS WITH PRELEUKEMIA. THYMUS, 8(1-2), 33-44.

RELATION OF AGE TO LYMPHOCYTE RADIOSENSITIVITY INVITRO
Knox, S. J., SHIFRINE, M., ROSENBLATT, L. S., Reeves, J. D., & Woerner, S. (1984). RELATION OF AGE TO LYMPHOCYTE RADIOSENSITIVITY INVITRO. HEALTH PHYSICS, 46(2), 431-433.

STUDIES OF LYMPHOCYTES-T IN PRELEUKEMIC DISORDERS AND ACUTE NONLYMPHOCYTIC LEUKEMIA - INVITRO RADIOSENSITIVITY, MITOGENIC RESPONSIVENESS, COLONY FORMATION, AND ENUMERATION OF LYMPHOCYTIC SUBPOPULATIONS
Knox, S. J., Greenberg, B. R., Anderson, R. W., & ROSENBLATT, L. S. (1983). STUDIES OF LYMPHOCYTES-T IN PRELEUKEMIC DISORDERS AND ACUTE NONLYMPHOCYTIC LEUKEMIA - INVITRO RADIOSENSITIVITY, MITOGENIC RESPONSIVENESS, COLONY FORMATION, AND ENUMERATION OF LYMPHOCYTIC SUBPOPULATIONS. BLOOD, 61(3), 449-455.

LYMPHOCYTE ABNORMALITIES IN PRELEUKEMIA .1. DECREASED NK ACTIVITY, ANOMALOUS IMMUNOREGULATORY CELL SUBSETS AND DEFICIENT EBV RECEPTORS
Anderson, R. W., Volsky, D. J., Greenberg, B., Knox, S. J., Bechtold, T., & Purtilo, D. T. (1983). LYMPHOCYTE ABNORMALITIES IN PRELEUKEMIA .1. DECREASED NK ACTIVITY, ANOMALOUS IMMUNOREGULATORY CELL SUBSETS AND DEFICIENT EBV RECEPTORS. LEUKEMIA RESEARCH, 7(3), 389-395.

RADIATION-INDUCED INHIBITION OF HUMAN-LYMPHOCYTE BLASTOGENESIS - THE EFFECT OF SUPEROXIDE-DISMUTASE AND CATALASE
Knox, S. J., Misra, H. P., SHIFRINE, M., & ROSENBLATT, L. S. (1982). RADIATION-INDUCED INHIBITION OF HUMAN-LYMPHOCYTE BLASTOGENESIS - THE EFFECT OF SUPEROXIDE-DISMUTASE AND CATALASE. INTERNATIONAL JOURNAL OF RADIATION BIOLOGY, 41(3), 283-294.

Growth of macrophage colonies from normal canine peripheral blood: morphological, cytochemical and functional parameters.
Knox, S. J., Wilson, F. D., Miller, C. H., ROSENBLATT, L. S., & SHIFRINE, M. (1982). Growth of macrophage colonies from normal canine peripheral blood: morphological, cytochemical and functional parameters. Stem cells, 1(6), 325-344.

ASSESSMENT OF THE INVITRO RADIOSENSITIVITY OF HUMAN PERIPHERAL-BLOOD LYMPHOCYTES
Knox, S. J., SHIFRINE, M., & ROSENBLATT, L. S. (1982). ASSESSMENT OF THE INVITRO RADIOSENSITIVITY OF HUMAN PERIPHERAL-BLOOD LYMPHOCYTES. RADIATION RESEARCH, 89(3), 575-589.

GROWTH OF HUMAN LYMPHOCYTE-T COLONIES FROM WHOLE-BLOOD - CULTURE REQUIREMENTS AND APPLICATIONS
Knox, S. J., Wilson, F. D., Greenberg, B. R., & SHIFRINE, M. (1982). GROWTH OF HUMAN LYMPHOCYTE-T COLONIES FROM WHOLE-BLOOD - CULTURE REQUIREMENTS AND APPLICATIONS. JOURNAL OF CELLULAR BIOCHEMISTRY, 18(1), 15-24.

CYTOGENETICS AND GRANULOPOIETIC EFFECTS OF BONE-MARROW FIBROBLASTIC CELLS IN FANCONIS ANEMIA
Greenberg, B. R., Wilson, F. D., Woo, L., Knox, S., Jenks, H., & Taplett, J. (1981). CYTOGENETICS AND GRANULOPOIETIC EFFECTS OF BONE-MARROW FIBROBLASTIC CELLS IN FANCONIS ANEMIA. BRITISH JOURNAL OF HAEMATOLOGY, 48(1), 85-93.

INCREASED RADIOSENSITIVITY OF A SUB-POPULATION OF LYMPHOCYTE-T PROGENITORS FROM PATIENTS WITH FANCONI ANEMIA
Knox, S. J., Wilson, F. D., Greenberg, B. R., SHIFRINE, M., ROSENBLATT, L. S., & Misra, H. (1981). INCREASED RADIOSENSITIVITY OF A SUB-POPULATION OF LYMPHOCYTE-T PROGENITORS FROM PATIENTS WITH FANCONI ANEMIA. BLOOD, 57(6), 1043-1048.

THE SELECTIVE GROWTH OF HUMAN LYMPHOCYTE-T COLONIES FROM WHOLE-BLOOD IN A SEMISOLID CULTURE SYSTEM
Knox, S. J., SHIFRINE, M., Wilson, F. D., & ROSENBLATT, L. S. (1981). THE SELECTIVE GROWTH OF HUMAN LYMPHOCYTE-T COLONIES FROM WHOLE-BLOOD IN A SEMISOLID CULTURE SYSTEM. EXPERIMENTAL HEMATOLOGY, 9(9), 926-937.

A WHOLE-BLOOD TECHNIQUE FOR THE QUANTITATION OF CANINE LYMPHOCYTE-T PROGENITORS USING A SEMISOLID CULTURE SYSTEM
Wilson, F. D., Dyck, J. A., Knox, S. J., & SHIFRINE, M. (1980). A WHOLE-BLOOD TECHNIQUE FOR THE QUANTITATION OF CANINE LYMPHOCYTE-T PROGENITORS USING A SEMISOLID CULTURE SYSTEM. EXPERIMENTAL HEMATOLOGY, 8(8), 1031-1039.

Cell-mediated immunity in the dog in relation to disease: A review.
Knox SJ, & Shifrine M. (1980). Cell-mediated immunity in the dog in relation to disease: A review. Comp Immun Microbiol Infect Dis, 2.

Susceptibility of clinical isolates of Pseudomonas aeruginosa to antimicrobial agents.
Hirsh DC, Wiger N, & Knox SJ. (1979). Susceptibility of clinical isolates of Pseudomonas aeruginosa to antimicrobial agents. Pharmacol Ther, 2.

PHARMACOKINETICS OF PENICILLIN-G IN TURKEY
Hirsh, D. C., Knox, S. J., CONZELMAN, G. M., & WIGER, N. (1978). PHARMACOKINETICS OF PENICILLIN-G IN TURKEY. AMERICAN JOURNAL OF VETERINARY RESEARCH, 39(7), 1219-1221.